Poxel Announces Updates to its Management Team

Download as PDF

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced changes in its management team, with the appointment of Quentin Durand as Chief Legal Officer, and the departure of Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and Executive Vice President (EVP) Late Development & Medical Affairs.

Quentin Durand joined Poxel from the international law firm of Dechert LLP where he served as a lawyer since 2015 in the Paris office. While at Dechert LLP, Quentin focused on corporate and securities matters with an emphasis on capital markets, including public company reporting and governance and worked closely with Poxel during this time. He was also involved in various merger and acquisition and equity capital market transactions both domestic and cross border across a wide range of industry sectors. Prior to working at Dechert LLP, Quentin served as a legal officer within the corporate finance division of the Autorité des marchés financiers and acted as a prosecutor before the Autorité des marchés financiers enforcement committee.

“We are delighted to welcome Quentin to the Poxel team. He knows the Company very well from the time he spent at Dechert LLP where he was actively involved in supporting Poxel on corporate, securities and governance matters,” said Thomas Kuhn, CEO of Poxel. “As Poxel continues to advance its business strategy, his legal expertise will be invaluable in helping the Company to execute against its plan.”

Additionally, Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and EVP Late Development & Medical Affairs, has left the Company to pursue other career opportunities.

“Christophe brought a wealth of expertise to Poxel. He led the Imeglimin TIMES program in Japan, which is now coming to completion and has reported successful clinical results from the TIMES 1 and TIMES 3 trials,” said Thomas Kuhn. “We would like to thank Christophe for the valuable contributions he made to Poxel and we wish him the very best in his future endeavors."

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Poxel SA

Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985

Aurélie Bozza
Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com
+33 6 99 81 08 36

Investor relations / Media - EU/US
Trophic Communications
Stephanie May or Joanne Tudorica
may@trophic.eu or tudorica@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
NewCap
Alexia Faure / Arthur Rouillé
poxel@newcap.eu
+33 1 44 71 94 94

Source: Poxel SA

Released November 29, 2019